Teresa Augustin1, Dmytro Oliinyk1, Josefine Rauch1, Viktoria Florentine Koehler2, Christine Spitzweg2,3, Claus Belka1,3, Lukas KÄsmann4,3. 1. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany. 2. Department of Internal Medicine IV, University Hospital, LMU Munich, Munich, Germany. 3. German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany. 4. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany; lukas.kaesmann@med.uni-muenchen.de.
Abstract
BACKGROUND/AIM: Metastatic anaplastic thyroid cancer is associated with a dismal prognosis. We evaluated outcome and prognostic factors in patients receiving radiation to the primary tumor in metastatic anaplastic thyroid cancer (ATC). PATIENTS AND METHODS: All consecutive patients with metastatic ATC (n=20) undergoing irradiation between 2009 and 2019 for anaplastic thyroid cancer were investigated. RESULTS: Median survival time and median progression-free survival were 2 (range=1-22) and 2 (1-20) months. In univariate analyses, surgery, concurrent or sequential chemotherapy and higher radiation dose escalation (>39 Gy) were correlated with longer overall survival (p=0.005, p=0.018 and p=0.038), respectively. Karnofsky performance status >70% showed a trend of longer survival time (p=0.062). Limited metastatic disease, surgery and concurrent/sequential chemotherapy are correlated with longer progression-free survival times (p=0.043, p=0.024 and p=0.039), respectively. CONCLUSION: Radiation to the primary tumor in metastatic anaplastic thyroid cancer is safe and offers durable local control. Treatment intensification including concurrent or sequential chemotherapy and radiation dose escalation were associated with longer survival rates and should be considered in selected patients with metastatic disease. Copyright
BACKGROUND/AIM: Metastatic anaplastic thyroid cancer is associated with a dismal prognosis. We evaluated outcome and prognostic factors in patients receiving radiation to the primary tumor in metastatic anaplastic thyroid cancer (ATC). PATIENTS AND METHODS: All consecutive patients with metastatic ATC (n=20) undergoing irradiation between 2009 and 2019 for anaplastic thyroid cancer were investigated. RESULTS: Median survival time and median progression-free survival were 2 (range=1-22) and 2 (1-20) months. In univariate analyses, surgery, concurrent or sequential chemotherapy and higher radiation dose escalation (>39 Gy) were correlated with longer overall survival (p=0.005, p=0.018 and p=0.038), respectively. Karnofsky performance status >70% showed a trend of longer survival time (p=0.062). Limited metastatic disease, surgery and concurrent/sequential chemotherapy are correlated with longer progression-free survival times (p=0.043, p=0.024 and p=0.039), respectively. CONCLUSION: Radiation to the primary tumor in metastatic anaplastic thyroid cancer is safe and offers durable local control. Treatment intensification including concurrent or sequential chemotherapy and radiation dose escalation were associated with longer survival rates and should be considered in selected patients with metastatic disease. Copyright
Authors: Glenn J Hanna; Naifa L Busaidy; Nicole G Chau; Lori J Wirth; Justine A Barletta; Antonio Calles; Robert I Haddad; Stefan Kraft; Maria E Cabanillas; Guilherme Rabinowits; Anne O'Neill; Sewanti A Limaye; Erik K Alexander; Francis D Moore; Krystof Misiwkeiwicz; Tom Thomas; Matthew Nehs; Ellen Marqusee; Stephanie L Lee; Pasi A Jänne; Jochen H Lorch Journal: Clin Cancer Res Date: 2018-01-04 Impact factor: 12.531
Authors: Todd A Pezzi; Abdallah S R Mohamed; Tommy Sheu; Pierre Blanchard; Vlad C Sandulache; Stephen Y Lai; Maria E Cabanillas; Michelle D Williams; Christopher M Pezzi; Charles Lu; Adam S Garden; William H Morrison; David I Rosenthal; Clifton D Fuller; G Brandon Gunn Journal: Cancer Date: 2016-12-27 Impact factor: 6.860
Authors: S Filetti; C Durante; D Hartl; S Leboulleux; L D Locati; K Newbold; M G Papotti; A Berruti Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Dan Fan; Jennifer Ma; Andrew C Bell; Andries H Groen; Kyrie S Olsen; Benjamin H Lok; Jonathan E Leeman; Erik Anderson; Nadeem Riaz; Sean McBride; Ian Ganly; Ashok R Shaha; Eric J Sherman; C Jillian Tsai; Jung J Kang; Nancy Y Lee Journal: Cancer Date: 2019-10-08 Impact factor: 6.860
Authors: Vivek Subbiah; Robert J Kreitman; Zev A Wainberg; Jae Yong Cho; Jan H M Schellens; Jean Charles Soria; Patrick Y Wen; Christoph Zielinski; Maria E Cabanillas; Gladys Urbanowitz; Bijoyesh Mookerjee; Dazhe Wang; Fatima Rangwala; Bhumsuk Keam Journal: J Clin Oncol Date: 2017-10-26 Impact factor: 44.544
Authors: Robert C Smallridge; Kenneth B Ain; Sylvia L Asa; Keith C Bible; James D Brierley; Kenneth D Burman; Electron Kebebew; Nancy Y Lee; Yuri E Nikiforov; M Sara Rosenthal; Manisha H Shah; Ashok R Shaha; R Michael Tuttle Journal: Thyroid Date: 2012-11 Impact factor: 6.568
Authors: Dagmar Führer; Jaume Capdevila; Lori J Wirth; Thomas Ernst; Santiago Ponce Aix; Chia-Chi Lin; Rodryg Ramlau; Marcus O Butler; Jean-Pierre Delord; Hans Gelderblom; Paolo A Ascierto; Angelica Fasolo; Marie Luise Hütter-Krönke; Patrick M Forde; Anna Wrona; Armando Santoro; Peter M Sadow; Sebastian Szpakowski; Hongqian Wu; Geraldine Bostel; Jason Faris; Scott Cameron; Andreea Varga; Matthew Taylor Journal: J Clin Oncol Date: 2020-05-04 Impact factor: 44.544